Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib

Kasper, Bernd; Dimitrakopoulou-Strauß, Antonia; Strauss, Ludwig G.; Hohenberger, Peter

doi:10.1007/s00259-010-1498-x

Cited by 45 publications

(27 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 27% decrease in the median average standardized uptake value (SUV) of the sequential PET examinations was demonstrated, with three patients demonstrating a Ն48% SUV decrease; no patient demonstrated a substantial increase in SUV. With further confirmation of these results, sequential PET imaging may serve as a surrogate marker allowing the detection of SUV changes after imatinib induction, helping to decide whether treatment should be continued or not [55]. However, given the low response rate with imatinib in patients with desmoid tumors, it is also possible that imatinib merely decreases glucose transporters as a biomarker for drug absorption independent of drug activity.…”

Section: Treatment Options For Advanced Diseasementioning

confidence: 99%

See 1 more Smart Citation

Desmoid Tumors: Clinical Features and Treatment Options for Advanced Disease

2011

Self Cite

View full text Add to dashboard Cite

Desmoid tumors describe a rare monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Although histologically benign, desmoids are locally invasive and associated with a high local recurrence rate, but lack metastatic potential. On the molecular level, desmoids are characterized by mutations in the ␤-catenin gene, CTNNB1, or the adenomatous polyposis coli gene, APC. Proof of a CTNNB1 mutation may be useful when the pathological differential diagnosis is difficult and location might be predictive for disease recurrence.Many issues regarding the optimal treatment of patients with desmoids remain controversial; however, surgery is the therapeutic mainstay, except if mutilating and associated with considerable function loss. Postoperative radiotherapy reduces the local recurrence rate, in cases of involved surgical margins. Because of the heterogeneity of the biological behavior of desmoids, including long periods of stable disease or even spontaneous regression, treatment needs to be individualized to optimize local tumor control and preserve patients' quality of life. Therefore, the application of a multidisciplinary assessment with multimodality treatment forms the basis of care for these patients. Watchful waiting may be the most appropriate management in selected asymptomatic patients. Patients with desmoids located at the mesentery or in the head and neck region could present with life-threatening complications and often need more aggressive treatment. This review describes treatment options and management strategies for patients with desmoid tumors with a focus on advanced disease. The Oncologist 2011;16:682-693

show abstract

Section: Treatment Options For Advanced Diseasementioning

confidence: 99%

“…In a pilot study, nine patients with progressive disease from a desmoid tumor receiving 800 mg of imatinib daily were studied [55]. Patients were examined with PET prior to the onset of therapy and during imatinib treatment.…”

Section: Treatment Options For Advanced Diseasementioning

confidence: 99%

Desmoid Tumors: Clinical Features and Treatment Options for Advanced Disease

2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…18) Conversely, Kasper, et al performed FDG-PET analysis of 16 patients with desmoid tumors, for whom the median SUV max was 4.1 (range: 1.0-8.1). 19) Although FDG-PET was useful for discriminating benign tumors from lung cancer recurrence, further emanation of PET for desmoid-type fibromatosis is needed.…”

Section: Discussionmentioning

confidence: 99%

A Case of Desmoid-Type Fibromatosis Arising after Thoracotomy for Lung Cancer with a Review of the English and Japanese Literature

Mori

Yamada

Ohba

et al. 2014

Ann Thorac Cardiovasc Surg

View full text Add to dashboard Cite

Chest wall desmoid-type fibromatoses are rare tumors 1) that occasionally arise from thoracotomy scars. 2,3) They are locally aggressive tumors that occasionally exhibit local recurrence after resection. 4) Desmoid tumors arising from thoracotomy scars in patients with lung cancer should be discriminated from chest wall recurrence or dissemination of lung cancer. To address this issue, we present our case and review cases of desmoid-type fibromatosis following a previous thoracotomy that were reported in English or Japanese. Case ReportA 62-year-old woman was found to have a chest wall tumor on chest computed tomography (CT) at a 1-year routine follow-up after video-assisted thoracoscopic segmentectomy for pT1aN0M0 lung adenocarcinoma. The tumor was 3.4 × 1.3 cm in size, and it was located in the previous thoracotomy site (Fig. 1A). Positron emission tomography (PET) revealed mild 18 F-fluorodeoxyglucose (FDG) accumulation in the tumor, with a maximal standardized uptake value (SUV max ) of 1.9. There was no effusion or other lesions on CT and PET. She had no apparent elevation of carcinoembryonic antigen (CEA; 1.9 ng/ml [normal range, <2.0 ng/ml]) compared to the preoperative CEA value of 1.3 ng/ml. CT-guided A Case of Desmoid-Type Fibromatosis Arising after Thoracotomy for Lung Cancer with a Review of the English and Japanese LiteratureTakeshi Mori, MD, PhD, Tatsuya Yamada, MD, Yasuomi Ohba, MD, PhD, Kentaro Yoshimoto, MD, PhD, Koei Ikeda, MD, PhD, Kenji Shiraishi, MD, PhD, and Makoto Suzuki, PhD, MD Chest wall desmoid-type fibromatoses are rare, locally aggressive tumors that occasionally arise from previous thoracotomy sites. Tumors arising from previous sites of thoracotomy to treat malignant disease should be discriminated from the pleural dissemination of the previous malignancy. In this study, we report a case of desmoid-type fibromatosis arising from a site for thoracotomy to treat lung cancer. Additionally we reviewed 15 reported cases of desmoid-type fibromatosis following thoracotomy and summarized their features. A 62-year-old woman was found to have a tumor on computed tomography (CT) at a 1-year routine checkup for lung cancer. The tumor (diameter, 3.4 cm) was located at the previous thoracotomy site. Positron emission tomography (PET) revealed mild 18 F-fluorodeoxyglucose (FDG) accumulation in the tumor, with a maximal standardized uptake value (SUV max ) of 1.9. CT-guided biopsy revealed only fibrous tissue. Eighteen months after the biopsy, CT revealed apparent tumor growth, and a biopsy revealed the same histology observed previously. The tumor was removed and diagnosed as desmoid-type fibromatosis. Currently, the patient is alive without recurrence 4 years after desmoid surgery.

show abstract

“…Although the radiological features of fibromatosis on CT or MR have been described in the literature, F-18 FDG-PET or PET/CT findings are rarely reported [7][8][9][10]. The F-18 FDG uptake in patients with fibromatosis ranged from low to moderate grade and was generally heterogenous with a few tiny foci of relatively intense uptake or relatively homogenous.…”

mentioning

confidence: 98%

F-18 FDG PET/CT Findings of Spontaneous Mesenteric Fibromatosis in a Patient with Gardner’s Syndrome

Sohn

Jeong

Lim

et al. 2011

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib

Abstract: To our knowledge, this is the first series of AF patients undergoing treatment with imatinib and monitored using sequential PET imaging, that allows detection of SUV changes after imatinib induction, thus helping to decide whether treatment should be continued or not.

Cited by 45 publications

References 34 publications

Desmoid Tumors: Clinical Features and Treatment Options for Advanced Disease

Desmoid Tumors: Clinical Features and Treatment Options for Advanced Disease

A Case of Desmoid-Type Fibromatosis Arising after Thoracotomy for Lung Cancer with a Review of the English and Japanese Literature

F-18 FDG PET/CT Findings of Spontaneous Mesenteric Fibromatosis in a Patient with Gardner’s Syndrome

Contact Info

Product

Resources

About